Groundbreaking immunotherapy offers hope for difficult tumors
Source: www.targetedonc.com Author: Sabrina Serani In an interview with Targeted Oncology, Mark Dybul, MD, discussed a breakthrough method of immunotherapy in solid tumors. Mark Dybul, MD Treatments for difficult-to-treat tumors like pancreatic cancer and triple-negative breast cancer are lacking in availability and efficacy. However, Mark Dybul, MD, identified that a key to treating these cancers lies in retraining a patient’s immune system. Unlike some approaches using exogenous immunomodulators, this method focuses on the patient's immune system. The dendritic cells are genetically modified from another person, enhancing immune stimulation. The combination of allergenic cells from another person, genetically modified dendritic cells, and tumor pieces aims to retrain the immune system to recognize and combat cancer differently. Preliminary data show promising results. In an interview with Targeted OncologyTM, Dybul, chief executive officer of Renovaro Biosciences, professor in the Department of Medicine at Georgetown University, and senior advisor at the Center for Global Health Practice and Impact, discussed how Renovaro’s breakthrough immunotherapy works and how it differs from currently available therapies. Targeted Oncology: What are some of the new immunotherapy technologies on the horizon? Dybul: The immunotherapies are, in our view, incredibly promising and exciting. [Renovaro’s] mission is to create a future free from toxic chemotherapy by retraining the immune system to recognize and control or eliminate a possible cancer and to have an ongoing ability to surveil and prevent recurrence. We believe it is very possible, and our preliminary data suggest that is the case. Our approach is to, again, [...]